Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

Razer is offering players a chance to get their hands on Battlefield 6 early access codes. The official Razer social pages ...

The Assault class is the frontline segment. They are responsible for pushing through enemy defenses using some of the most ...

Reports Q2 revenue $965,000, consensus $433,330. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory ...